Sang­amo lays off 160+ staffers, winds down fa­cil­i­ty, punts clin­i­cal pro­grams in dras­tic re­vamp

Months af­ter chop­ping about a quar­ter of its US work­force, Sang­amo Ther­a­peu­tics is back with an­oth­er round of lay­offs to tight­en its belt. As the Cal­i­for­nia biotech clos­es down a fa­cil­i­ty in Bris­bane ear­ly next year, it will be cut­ting an­oth­er 40% of the re­main­ing crew, or 162 roles.

Sang­amo says it’s look­ing to sim­pli­fy the or­ga­ni­za­tion and fo­cus on its epi­ge­net­ic reg­u­la­tion ther­a­pies to treat neu­ro­log­i­cal dis­eases, as well as AAV cap­sid de­liv­ery tech­nolo­gies. That will mean sus­pend­ing new in­vest­ment in and of­fload­ing two of its most ad­vanced pro­grams — in­clud­ing a gene ther­a­py for Fab­ry dis­ease and a CAR-Treg pro­gram for au­toim­mune con­di­tions, both of which are in Phase I/II tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.